The global antidepressant drugs market size was US$ 18.1 billion in 2021. The global antidepressant drugs market is forecast to grow to US$ 32 billion by 2030, registering a compound annual growth rate (CAGR) of 6.55% during the forecast period from 2022 to 2030. 

Factors Influencing the Market

• Rising cases of depression globally are driving the growth of the global antidepressant drugs market. In addition, increasing awareness about the efficient treatments and the introduction of novel drugs is forecast to fuel the growth of the global antidepressant drugs market. 
• Improper eating habits and stressful work schedule is the major cause of depression. Thus, the growing number of the working population and busy schedules are forecast to offer ample growth opportunities for the market players. 
• The increasing geriatric population and growing changes in lifestyle will accelerate the growth of the global antidepressant drugs market. 
• Poor efficiency and safety concerns regarding drugs may hamper the growth of the global antidepressant drugs market during the study period. 

COVID-19 Impact Analysis

The COVID-19 pandemic has severely impacted the mental health of the majority of the population. People globally suffered from stress, anxiety due to job loss, quarantine, and other factors. As a result, the demand for antidepressant drugs decreased drastically. Moreover, governments across various nations took the initiative to help depression survivors. The Coronavirus Aid, Relief, and Economic Security Act (CARES) offered around US$ 425 million to the Substance Abuse and Mental Health Services Administration in order to expand mental health services for isolated people via telehealth and other related services.

Regional Analysis

North America holds the largest share in the global antidepressant drugs market. One of the major factors expected to drive the overall growth of the antidepressant drugs market is the rising cases of depression. Furthermore, the geriatric population in the United States is growing, which is forecast to create more opportunities for market players in the region. Anxiety disorder is one of the most common mental illnesses in the United States, affecting approximately 40 million American adults each year, or 18.1 percent of the total population, according to the estimations by the Anxiety and Depression Association of America. Furthermore, more than 16.1 million American adults suffer from major depressive disorder each year, with women being more affected than men. As a result, the increasing prevalence of these disorders and the increasing rate of antidepressant consumption are forecast to drive the market during the study period.

Competitors in the Market

• AstraZeneca
• Eli Lilly and Company
• GlaxoSmithKline PLC
• H. Lundbeck AS
• Johnson & Johnson
• Pfizer Inc.
• Merck & Co. Inc.
• Sanofi
• Sun Pharmaceuticals Pvt Ltd
• Alkermes
• Bristol Myers Squibb Company
• Teva Pharmaceutical Industries
• Eli Lilly and Co.
• Takeda Pharmaceutical Co. Ltd
• Forest laboratories
• Akeda Pharmaceutical
• Other Prominent Players

Market Segmentation

The global antidepressant drugs market segmentation focuses on Depression Disorders, Products, and Region.

By Depression Disorder

• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others

By Product

• Tricyclic Antidepressants
• Selective Serotonin Reuptake Inhibitors
• Serotonin-norepinephrine reuptake Inhibitors
• Monoamine oxidase inhibitors
• Serotonin antagonist and reuptake inhibitors
• Others

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America